OncLive TV

Lee S. Schwartzberg, MD, FACP, explains how biosimilars could lead to increased competition in oncology.

Robert L. Coleman, MD, FACOG, FACS, discusses ongoing research efforts in cervical cancer.

Georgina V. Long, BSc, PhD, MBBS, FRACP, discusses the rationale for the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with melanoma who have brain metastases.

Mary J. Fidler, MD, discusses the results of the phase III RELAY trial in treatment-naïve patients with EGFR-mutant non–small cell lung cancer.

Ajay K. Nooka, MD, MPH, FACP, discusses current options for transplant-eligible and -ineligible patients with multiple myeloma.

Carlos E. Vargas, MD, discusses toxicities associated with stereotactic body radiation therapy compared with standard fractionated radiation therapy in prostate cancer.

Simon Rule, MD, PhD, discusses what the treatment landscape of mantle cell lymphoma may look like in the next decade.

Mark G. Kris, MD, discusses the ongoing search for additional biomarkers in advanced squamous non­–small cell lung cancer.

Ivan M. Borrello, MD, discusses treatment for patients with indolent versus aggressive relapsed multiple myeloma.

Keerthi Gogineni, MD, MSHP, discusses the clinical implications of the phase II APT trial in HER2-positive breast cancer.

Allyson Ocean, MD, discusses efforts to improve early detection rates in pancreatic cancer.

Floor J. Backes, MD, discusses the safety profile from a phase I study looking at lenvatinib and weekly paclitaxel in women with recurrent endometrial cancer.

Erika P. Hamilton, MD, discusses the impact of biosimilars in oncology.

Eric Jonasch, MD, discusses how to modulate the tumor microenvironment in renal cell carcinoma.

Ghanshyam Yadav, MD, discusses the differences between type 1 and type 2 uterine cancer.

Jim M. Koeller, MS FHOPA, discusses the heterogeneity of biologics.

Brendon Stiles, MD, discusses considerations for surgery in lung cancer.

Cathy Eng, MD, FACP, FASCO, discusses unique barriers facing patients with early-onset colorectal cancer.

Thai H. Ho, MD, PhD, discusses the role of TKI monotherapy in the first-line treatment of patients with metastatic renal cell carcinoma.

Casey M. Cosgrove, MD, discusses factors to consider when selecting a PARP inhibitor as maintenance therapy in advanced ovarian cancer.

Sagar Lonial, MD, FACP, discusses the management of patients with relapsed multiple myeloma.

David F. McDermott, MD, discusses the combination of VEGF TKIs and PD-1 inhibitors in advanced renal cell carcinoma.

Michael D. Offin, MD, discusses targeted agents in MET- and RET-altered non–small cell lung cancer.

Bradley G. Somer, MD, discusses lowering the cost of cancer care with biosimilars.

Kathleen G. Essel, MD, discusses the rationale to explore quantitative computed tomography image feature analysis in gynecologic cancers.

Kurt Tauer, MD, FACP, discusses arguments in favor of and against biosimilars in oncology.

W. Victoria Lai, MD, discusses the results of the phase III CASPIAN trial in small cell lung cancer.

Leigha Senter, MS, LGC, discusses the implications of identifying genes beyond BRCA1/2 in women with ovarian cancer.

David Polsky, MD, PhD, discusses potential applications of circulating tumor DNA as a biomarker in melanoma.

Ruth O’Regan, MD, discusses the prognostic value of pathologic complete response in HER2-positive breast cancer.